Key Events This Week
15 Jun: Week opens at ₹2,380.60 with marginal gain
16 Jun: Stock dips 1.00% amid low volume
18 Jun: Sharp rebound with 1.75% gain following positive technical signals
19 Jun: MarketsMOJO upgrades rating to Buy; stock closes at ₹2,417.35 (+0.52%)
15 June 2026: Week Opens with Marginal Gain Amid Broad Market Rally
Mankind Pharma commenced the week at ₹2,380.60, posting a slight increase of 0.05% on relatively strong volume of 80,947 shares. This modest gain came despite the Sensex surging 1.19% to 35,764.67, reflecting a cautious start for the stock amid broader market optimism. The stock traded within a narrow range, maintaining stability above its recent support levels.
16 June 2026: Price Declines 1.00% on Thin Volume
The stock experienced a notable dip on 16 June, falling 1.00% to ₹2,356.75 on sharply reduced volume of just 6,422 shares. This decline contrasted with the Sensex’s continued upward trajectory, which gained 0.49% to 35,939.94. The subdued trading activity suggested profit-taking or short-term caution among investors, possibly awaiting fresh catalysts to drive momentum.
17 June 2026: Recovery Begins with 0.29% Gain
On 17 June, Mankind Pharma rebounded modestly, closing at ₹2,363.50, up 0.29% on volume of 45,794 shares. The Sensex also advanced 0.52% to 36,125.82, indicating a broadly positive market environment. The stock’s recovery was supported by stabilising technical indicators, setting the stage for a stronger move later in the week.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
18 June 2026: Strong 1.75% Rally on Positive Technical Momentum
The stock surged 1.75% to close at ₹2,404.95 on 18 June, buoyed by renewed technical strength and improving momentum indicators. Volume remained moderate at 11,061 shares. This rally outpaced the Sensex’s 0.44% gain to 36,284.69, signalling a shift in investor sentiment. Key technical indicators such as the weekly MACD turned bullish, and the stock traded near its upper Bollinger Band, reinforcing the positive outlook.
19 June 2026: MarketsMOJO Upgrades to Buy; Stock Closes at ₹2,417.35
On the final trading day of the week, Mankind Pharma’s stock price advanced 0.52% to ₹2,417.35 on volume of 14,491 shares, despite the Sensex retreating 0.30% to 36,174.54. The upgrade by MarketsMOJO from Hold to Buy, announced on 18 June, was a key catalyst. The rating change reflected strong financial performance, robust operating margins, and a favourable technical setup. The company’s Mojo Score improved to 72.0, signalling renewed investor confidence.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-15 | Rs.2,380.60 | +0.05% | 35,764.67 | +1.19% |
| 2026-06-16 | Rs.2,356.75 | -1.00% | 35,939.94 | +0.49% |
| 2026-06-17 | Rs.2,363.50 | +0.29% | 36,125.82 | +0.52% |
| 2026-06-18 | Rs.2,404.95 | +1.75% | 36,284.69 | +0.44% |
| 2026-06-19 | Rs.2,417.35 | +0.52% | 36,174.54 | -0.30% |
Key Takeaways: Strong Fundamentals and Technical Momentum Amid Mixed Market
Mankind Pharma’s week was characterised by a gradual recovery from mid-week weakness, culminating in a positive close supported by a rating upgrade and bullish technical signals. The company’s financial metrics remain robust, with operating profit margins at 27.01% and a high Return on Capital Employed of 20.79%, underscoring operational efficiency. The upgrade to a Buy rating by MarketsMOJO, accompanied by a Mojo Score of 72.0, reflects confidence in the stock’s medium-term prospects.
Technical indicators showed a clear shift towards bullish momentum, particularly on weekly charts where MACD and Bollinger Bands signalled strength. However, some monthly indicators remain mildly bearish, suggesting that investors should monitor for confirmation of sustained upward trends. Volume trends were mixed, with on-balance volume mildly bearish weekly but neutral monthly, indicating that price gains are not yet fully volume-supported.
Despite the stock’s 1.59% weekly gain, it underperformed the Sensex’s 2.35% rise, reflecting some relative caution. The stock’s valuation remains elevated, with a PEG ratio of 33, signalling high growth expectations that may limit upside if earnings growth slows. Institutional ownership at 24.7% indicates solid backing from sophisticated investors.
Want to dive deeper on Mankind Pharma Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Conclusion: A Week of Technical and Fundamental Validation
The week ending 19 June 2026 saw Mankind Pharma Ltd consolidate its position as a fundamentally sound and technically supported stock within the pharmaceutical sector. The MarketsMOJO upgrade to Buy, driven by strong financial performance and improved technical momentum, provides a positive backdrop for the stock’s near-term trajectory. While some caution is warranted due to valuation levels and mixed monthly technical signals, the overall outlook remains constructive.
Investors should continue to monitor volume trends and broader market conditions as the stock attempts to build on this week’s gains. The company’s solid operating metrics and institutional support offer a foundation for sustained performance, even as short-term volatility may persist.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
